DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Suneva Medical-Viveon Health merger update; Smith+Nephew acquires Engage Surgical; Abiomed's preCARDIA technology; Medtronic’s DTM Spinal Cord Stimulation; Endo Tools Therapeutics’s Endomina System; Diadem's AlzoSure predict prognostic blood test Visit Post
2 Biogen-Eisai's Aduhelm; Quidel acquires Ortho Clinical Diagnostics; Accutar Biotechnology’s AC0176; Boehringer’s Spesolimab Visit Post
3 Aslan Pharma - IQVIA collaboration; Reata's kidney drug bardoxolone; Alzheimer’s Disease treatment update; Recordati to acquire EUSA Visit Post
4 LensGen’s Juvene Intraocular Lens; Nevro announces clinical data publications; FDA Clearance to Immunexpress’s SeptiCyte; GE unveils AI and Digital Technologies; Canon launches PIQE DLR and SilverBeam; Hyperfine’s Swoop gets FDA clearance Visit Post
5 Neurent Medical’s NEUROMARK; Brain Navi NaoTrac received European CE Mark approval; Theradaptive receives Breakthrough Medical Device Designation; HAGAR GWave awarded Breakthrough Device Designation; Fujifilm launches ColoAssist PRO Visit Post
6 TecTraum’s pro2cool receives Breakthrough Device Designation; Vektor Obtains FDA Clearance for vMap; Medtronic’s TMVR system; Sight Sciences's PRECISION Trial; Alcon to buy Ivantis; Philips to acquire Cardiologs Visit Post
7 Smith+Nephew's LEGION CONCELOC; Renew Bioscience's Cerezen; Perimeter Medical's ATLAS AI Project; SAGA Diagnostics-AZ's Deal; Magnus Receives Breakthrough Device Designation; ReValve's Transeptal Mitral Valve Replacement Visit Post
8 An in-depth Assessment of the Top Drugs Launched by Leading Global Companies in the First Half of 2021 (H1) Visit Post
9 Biogen's ALS drug Tofersen (BIIB067); Phathom's erosive esophagitis drug trial; Vertex's islet cell therapy; Natera launches lung DNA test Visit Post
10 Brickell to Submit New Drug Application to FDA; Twin Health Raises $140M; BMS' Deucravacitinib; Lando Biopharma’s LABP-104 gets Approval; NIH Grant of $ 3 M to Amydis; FDA Grant to GenSight’ GS030 Visit Post
11 Evaluating the Role of Digital Therapeutics as an Alternative to Conventional Therapies for Depression Visit Post
12 Amber Implants VCFix spinal system; iotaMotion's iotaSOFT Insertion System; Boston Scientific acquires Baylis; ReCor's Paradise Ultrasound Renal Denervation; Boston Scientific's Ranger Drug-Coated Balloon; Natera's Prospera Visit Post
13 RETINA-AI Health declares positive results; Medtronic's Hugo robotic-assisted surgery system; Boston Scientific acquires Devoro Medical; Paige obtains first-ever FDA approval Visit Post
14 UNION Therapeutics-Innovent's collaboration; Delix Therapeutics bags $ 70 M; Biohaven’s Verdiperstat clinical trial result; Intra-Cellular's CAPLYTA Phase III study Visit Post
15 FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises Visit Post
16 Ascendis's SKYTROFA; MicroTransponder’s VNS System (Vivistim); BioMarin's Voxzogo; Zimmer-Canary's Smart Knee Implant; COVID-19 impact on Solid Organ Transplants Visit Post
17 Sanofi bets $3.2B on mRNA; Marinus signs $30M deal with Orion; Mestag with $45M seed; Moderna secures fast track designation Visit Post
18 Amgen acquires Teneobio for $2.5B; Signifier scores $35M; Biogen-Ionis’ drug meets a goal; AbbVie hits go on $1B re-upped Calico deal Visit Post
19 MedTech Market Industry: Approval of Devices, Therapy Address Market Needs | Clinical Outcomes Create New Value Visit Post
20 Insilico Medicine raises $255M; Sanofi & Translate Bio initiate trial; Medtronic gains expanded FDA approval; Blackstone, Cellex & Intellia form CAR-T startup Visit Post
21 Does the use of Assistive Technologies in Autism Spectrum Disorder Payoff? Visit Post
22 Mallinckrodt earns FDA nod for skin therapy; RayzeBio secures $108M; VectorY raises $38M; Umoja banks $210M Visit Post
23 Eclipse, Medtronic, Aethlon, Cognoa, ObvioHealth, and others Continue to Veer MedTech Market Forward Visit Post
24 Medical Devices Market Blooms as the Key MedTech Companies Continue to Bring-In Innovation Visit Post
25 Spinal Stenosis Devices Market Size to Balloon Up Owing to Increasing Prevalence & Geriatric Population, as well as Medical Advancements Visit Post
26 Migraine Market: How Pharma Companies are trying to Uncomplicate the Disease and Bring in Novel Therapies Visit Post
27 Biogen’s Alzheimer’s Drug; FDA approval to Novo Nordisk’s Wegovy; Bluebird's Gene Therapy Visit Post
28 MedTech Industry Roars Back as FDA Approvals Soar Visit Post
29 Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med Visit Post
30 Drug Development and Pipeline Analysis in the Alzheimer’s Disease Market Space Visit Post
31 How Depression Is Eroding The Mental And The Physical Health Of The Society? Visit Post
32 Bright Peak, Ajinomoto to Create Novel Immunocytokines; FDA’s Rejection to Lilly/Pfizer's Tanezumab for Osteoarthritis Pain; Ikena Oncology Unveils IPO Pricing Visit Post
33 Asher Bio raises $55M; Roche halts Huntington's phase 3 trial; Novartis' radioligand hits goal in phase 3; EpimAb raises $120M in Series C Visit Post
34 Which Pharma Companies are Transforming the Drug-Resistant Epilepsy Market Landscape? Visit Post
35 GBT strikes a deal with Sanofi; Lilly's IL-23 inhibitor shows promise; Glooko raises $30M; FDA uplifts hold on Solid’s DMD gene therapy Visit Post
36 Emerging Therapies in the Chronic Pain Pipeline Transforming the Chronic Pain Market Landscape Visit Post
37 Valo Health receives $110M Series B Cognito's therapy slows Alzheimer's disease Ventyx Biosciences raises $114M Takeda expands immuno-oncology portfolio Visit Post
38 Gene and Cell Therapies in CNS Disorders: Miracle Cure? Opportunities Galore! Visit Post
39 Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval Visit Post
40 Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda's Maribavir; Astellas/Seagen Padcev Visit Post
41 Notorious Hyperkalemia: What are the causes, signs and new treatments? Visit Post
42 Eating Disorders: What Happens When Stigma And Misconceptions Command The Health Visit Post
43 The Burden And The Impact Of Mental Health Issues In Today’s Time Visit Post
44 Biohaven's Troriluzole Failure; Daiichi/ AZ's Enhertu; Fujifilm & Manufacturing Spree; J&J's Darzalex Faspro Visit Post
45 Parkinson's Disease: How close are we to a cure? Visit Post
46 Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL; SanBio STEMTRA Phase 2 Interim Results Visit Post
47 Watch Out For Top Pipeline Therapies Making An Impact In The Bipolar Depression Market Visit Post
48 21 of the most common questions about Epilepsy Visit Post
49 Mitochondria destruction for Cancer Treatment; Atsena raises USD 55 Million financings; Novartis and Cadent Therapeutics collaboration; Neuron23’s strategy to tackle CNS disorders Visit Post
50 Top Emerging Therapies To Watch Out for in the Retinal Vein Occlusion Market Visit Post
51 What are the options available for the treatment of Retinal vein occlusion? Visit Post
52 Santhera flunks DMD phase 3; Scribe emerges with $20 M; Merck sells off Osteoarthritis drug to Novartis; Research updates on flu vaccine and glioblastoma Visit Post
53 FDA rejects BioMarin's Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes Visit Post
54 Gilead's remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche's cancer drug Visit Post
55 MorphoSys, Incyte receive FDA Ok for Monjuvi; Siemens Healthineers set to buy Varian; Immunic's IMU-838 promising results Visit Post
56 Roche-UCB's $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures Visit Post
57 Addressing The Scattered Harbingers of Frontotemporal Dementia Visit Post
58 Amylyx Raises $30M; QurAlis Announces License Agreement Deal With Lilly; COVID-19 Vaccine Updates; Researchers Develop a New Ultrafast Insulin Visit Post
59 Regeneron's I-O Drug; Gene Therapy for Parkinson's Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M Visit Post
60 Can Alzheimer's be cured with Marijuana? Visit Post
61 The Question That Remains Unanswered: What Might Be Causing Alzheimer’s? Visit Post
62 Can Aducanumab Slove the Puzzle Of Alzheimer’s? Visit Post
63 When Technological Innovations Help in Remembering for People Living with Alzheimer’s Visit Post
64 Gene-edited T cells for diabetes treatment; Pliant raised $144 million; Accent, AstraZeneca aim RNA modifiers in cancer deal; NodThera Raises $55M; Visit Post
65 What are the 10 early signs of Alzheimer’s that are overlooked? Visit Post
66 An Ageing Population and Upcoming Therapies: What is shaping the Alzheimer’s Disease Market Scenario? Visit Post
67 Startup focuses tumors with CAR-T; AbCellera grabs USD 105M; Gilead inks USD 2B deal; GSK’s anti-BCMA antibody receives a boost Visit Post
68 CanSino deals with Precision; Atea raises USD 215 M; Applied Molecular Transport targets for USD 100 M IPO; Cell therapy repairs multiple sclerosis in mice Visit Post
69 Acquisition of Stemline; Roche’s Elecsys Anti-SARS-CoV-2 antibody test; Newron’s abandonment of STARS trial Visit Post
70 Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials Visit Post
71 AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes Visit Post
72 Parkinson’s Disease Market: Impact of Emerging therapies on Parkinson’s therapeutics market Visit Post
73 Evotec, Vifor Pharma collaborates to cure kidney diseases; AZ takes major steps to advance pharma and medicine R&D in China; Amneal licenses-in a Myasthenia Gravis drug from Kashiv BioSciences Visit Post
74 AZ sells EU rights for Schizophrenia to Cheplapharm; Astellas, Pandion unite to extract the potential of immunomodulation; Pear therapeutics on a journey to develop digital GI treatments with Ironwood Visit Post
75 Biogen seeks the FDA approval to revive its Alzheimer’s drug Aducanumab Visit Post
76 EicOsis receives USD 15M to fuel its non-opioid pain therapy; Alexion Pharmaceuticals buys Achillion Pharmaceuticals; Ipsen adds another drug to its rare disease pipeline Visit Post
77 A New Era for Migraine Treatment and CGRP antibodies Visit Post
78 World Alzheimer’s Day Visit Post
79 DRUG-RESISTANT EPILEPSY Visit Post
80 Parkinson's Disease: 5 stages, Risk Factors, Prevention, Gene Therapy Visit Post
81 NICE endorsement for Pfizer’s Vizimpro; Eisai, Dundee targets Cancer; Capital raise for AgaMatrix Visit Post
82 Post-Traumatic Stress Disorder Day Visit Post
83 The era of Gene therapy, and the Billion Dollar tag Visit Post
84 World Multiple Sclerosis Day Visit Post
85 Meet the World's most expensive drug: Zolgensma Visit Post
86 Spinal Muscular Atrophy Market Visit Post
87 Spinal Muscular Atrophy: Current and Emerging Therapies Visit Post
88 Parkinson's Awareness Month 2019 Visit Post
89 Spinal Muscular Atrophy Market is expected to augment at a CAGR of 10.42% Visit Post
90 Can Spinal Muscular Atrophy be treated by Protease Inhibitors? Visit Post
91 Notizia Visit Post
92 Global Parkinson’s Therapeutic Market Outlook Visit Post
93 Beta Interferons prolongs life in Multiple Sclerosis Visit Post
94 What can be the scope of Medical Marijuana? Visit Post
95 Notizia Visit Post
96 Alzheimer's drug fails! Is it time to move on? Visit Post
97 Notizia Visit Post
98 Biogen buys Nightstar; Pacira acquires Myoscience; Horizon Pharma announces pricing; STAT with Slingshot Insights; Epizyme announces Equity Offering Visit Post
99 Notizia Visit Post
100 The antidepressant drug gets support from FDA Visit Post
101 Antidepressant of J&J leads to FDA; SCLC model discloses; Genes and macular degeneration can disclose new treatment ways Visit Post
102 Notizia Visit Post
103 Juvenescence raises $46M; Brainsway files for IPO; Life Biosciences raises Visit Post
104 Attention-Deficit/Hyperactivity Disorder (ADHD) Visit Post
105 The lab-grown mini-brains generate electrical patterns Visit Post
106 ‘Invisible’ mice reveal anatomical secrets Visit Post
107 Antidepressants withdrawal hits millions of people Visit Post
108 Notizia Visit Post
109 Voltage-Dependent T-Type Calcium Channel Blockers  Visit Post
110 Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial Visit Post
111 Novartis ventures; Bill Gates invests; Arcus Biosciences gains; Denali and Odonate seek funding; Fosun Pharma acquires Visit Post
112 Reprogrammed cells relieve Parkinson's symptoms in trials Visit Post
113 Samsung biosim nod sets; Lilly's med hits; BioMarin sees pricing; Spinraza scores; Klick creates Visit Post
114 Biogen triumphs; Lilly, Pfizer, Ipsen back; Court nixes; Mylan EpiPen recall Visit Post
115 Mylan closing Illinois plant; Insys spends $24M; Roche's Ocrevus; Greece’s corruption prosecutor quits Visit Post
116 SEC scrutinizes; Acacia meets endpoint; Axovant's dementia drug; Novartis expands; Aurobindo responds Visit Post
117 NMDA Receptor Antagonist: Emerging therapies in CNS Visit Post
118 Fatal French clinical trial failed to check data before raising dose Visit Post
119 Novartis joins; Sanofi weighs Actelion; Valeant and Takeda's $10B deal; Astellas scouts pipeline Visit Post
120 The Snippet: The Success of Cannabidiol Visit Post
121 Roche's drug; Cancer drugs risk; FDA norms; Takeda sets deal Visit Post
122 Treatment for esophageal cancer; FDA bans soaps; Dr Reddy's Launches; Cipla Gets Approval Visit Post
123 Identity Crises Faced by a Venerable Brain-Cancer Cell Line Visit Post
124 BI & Duke Clinical Research Institute have expansion; BioInvent Inks Mfg. Pact; Elite Pharma, SunGen Pharma in Development & License Deal; Boehringer and Saniona Develop new Compounds; BioLineRx and I-Bridge Capital Establish; Alliance between Harvard and Tata Companies; Innovative Targeting Solutions and Johnson & Johnson Innovation collaborate Visit Post
125 Denali's Impressive Research Portfolio Visit Post
126 NATCO Pharma surges; AstraZeneca falls; US patent office rules Visit Post
127 Fatty Acid Amide Hydrolase (FAAH) Inhibitors - Pipeline Insights, 2015 - A DelveInsight’s Report Visit Post
128 DelveInsight’s Central Nervous System Disorders based Gene Therapy Reports Visit Post
129 Brain Hemorrhage-Pipeline Insights, 2014 Visit Post